Get the Stockscreener App
734.57
2.25%
-16.88
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $734.57, with a volume of 3.95M.
It is down -2.25% in the last 24 hours and down -2.54% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$751.45
Open:
$752.01
24h Volume:
3.95M
Relative Volume:
1.04
Market Cap:
$739.39B
Revenue:
$49.00B
Net Income/Loss:
$11.11B
P/E Ratio:
59.77
EPS:
12.29
Net Cash Flow:
$-1.27B
1W Performance:
-10.81%
1M Performance:
-2.54%
6M Performance:
-11.66%
1Y Performance:
-4.79%
1-Day Range:
$733.00
$762.01
1-Week Range:
$733.00
$829.64
52-Week Range:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
734.57 | 739.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.22 | 375.64B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
184.60 | 351.09B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
65.77 | 307.32B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
108.70 | 225.73B | 53.22B | 12.86B | 14.85B | 6.39 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Lilly's $250 million investment with Purdue sure to benefit Lebanon - reporter.net
PRIMECAP Management's Strategic Moves: A Closer Look at Eli Lilly and Co - Yahoo Finance
Lilly, Purdue expand initiative for drug development - WISH-TV
Eli Lilly, Purdue announce $250M research collaboration - Mirror Indy
Lilly to invest up to $250M in broadened alliance with Purdue University - dailyjournal.net
Eli Lilly and Purdue University Forge $250 Million Alliance to Advance Pharmaceutical Innovation in Indiana - Hoodline
Eli Lilly extends Purdue alliance; EMA investigates Valneva shot - BioPharma Dive
Eli Lilly outlines support for Trump’s plans to ‘repatriate’ supply chains back to the US - Business Post
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire Inc.
'Blazing a new trail' | Eli Lilly to invest up to $250 million in expanded partnership with Purdue - WTHR
Eli Lilly, Purdue to expand partnership with $250 million investment - CBS 4
‘Innovation at every stage’: Lilly to invest up to $250M in broadened alliance with Purdue - Inside INdiana Business
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation - Purdue University
Eli Lilly & Co. (LLY) to expand Purdue University collaboration with up to a $250M investment to accelerate pharmaceutical innovation - StreetInsider
Dividend Roundup: Eli Lilly, Pepsico, Ford, Delta Air Lines, and more - Seeking Alpha
Rx Rundown: Eli Lilly, Teva, Vivo Capital and more - Medical Marketing and Media
Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment - Endpoints News
Governor breaks ground on $4.5 billion Lilly Medicine Foundry in Lebanon - Greensburg Daily News
Eli Lilly, Novo Nordisk report strong earnings as GLP-1 race heats up - Healthcare Brew
Eli Lilly and Company (LLY) Announces Results of 2025 Annual Sha - GuruFocus
Eli Lilly & Co Shareholders Vote on Key Issues - TipRanks
Eli Lilly (NYSE:LLY) Announces Executive Changes To Drive Global Growth And Pipeline Advancement - simplywall.st
Top Stock Movers Now: AB InBev, Molson Coors, Eli Lilly, and More - MSN
Lilly shuffles roles amid growth in U.S. investment, diabetes and obesity treatments - Inside INdiana Business
Eli Lilly falls, Arm reacts to chip curbs, D-Wave skyrockets - Yahoo Finance
Palantir, Eli Lilly lead Thursday’s market cap stock movers By Investing.com - Investing.com Canada
FDA, Lilly Score Win in Weight Loss Drug Shortage Decision (1) - Bloomberg Law News
Eli Lilly (LLY) Restructures Leadership to Propel U.S. Growth - GuruFocus
Are Wall Street Analysts Bullish On Eli Lilly Stock? - Barchart.com
Eli Lilly shifts executive roles to spur growth - Investing.com
Lilly names new executives in leadership transition (LLY:NYSE) - Seeking Alpha
Lilly announces transitions in executive leadership | Eli Lilly and Company - Eli Lilly and Company
Eli Lilly & Co. (LLY) Announces Leaderhsip Changes - StreetInsider
Lilly announces transitions in executive leadership - Stock Titan
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Down Nearly 20%: Should You Buy the Dip on Eli Lilly? - MSN
'We are all richer for having had him in our lives': Patrick Holden dies after 500 Festival run - IndyStar
FDA Gets Win In Eli Lilly Weight Loss Drug Shortage Fight - Law360
US judge sides with FDA's removal of Lilly's weight loss drug from shortage list - Reuters
Judge Upholds FDA Decision Ending Zepbound Shortage, Favoring Eli Lilly (LLY) - GuruFocus
Lilly benefits as judge upholds FDA removing Zepbound from shortages list - Seeking Alpha
Eli Lilly and Company (LLY): A Bull Case Theory - MSN
Lilly chief scientist talks drugmaker’s new $4.5B campus, recruiting and innovation - Indianapolis Business Journal
Jim Cramer Says Eli Lilly and Company (LLY) CEO David Ricks Is ‘Very Conservative’ - Yahoo Finance
Construction begins on $4.5 billion Eli Lilly facility in Lebanon - WFYI
Eli Lilly & Co. (LLY) option IV flat - StreetInsider
'A completely new kind of facility' | Lilly breaks ground on new medicine foundry in Lebanon - WTHR
Lilly breaks ground on $4.5B foundry campus in Lebanon’s LEAP District - Indianapolis Business Journal
Lilly breaks ground on $4.5 billion R&D facility - WISH-TV
Eli Lilly Stock Is Sliding Tuesday: What's Going On? - Benzinga
Eli Lilly In Lebanon - wowo.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):